Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Ascrinvacumab |
| Trade Name | |
| Synonyms | PF-03446962|GT90001|GT-90001|GT 90001 |
| Drug Descriptions |
Ascrinvacumab (PF-03446962) is a monoclonal antibody that binds and inhibits activin-like receptor kinase 1 (ALK-1), potentially resulting in decreased tumor angiogenesis and proliferation (PMID: 31444620). |
| DrugClasses | |
| CAS Registry Number | 1463459-96-2 |
| NCIT ID | C91073 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Ascrinvacumab | Ascrinvacumab | 0 | 0 |
| Ascrinvacumab + Nivolumab | Ascrinvacumab Nivolumab | 0 | 1 |
| Ascrinvacumab + Regorafenib | Ascrinvacumab Regorafenib | 0 | 1 |